New research summarized with the original sources. New protocols added to the manual. What's hype, what's signal — sent Sunday morning to readers including clinicians, coaches, and informed self-experimenters.
The most important readout, paper, or pipeline update of the week — summarized in 250 words with the primary citation linked.
The one viral wellness claim from this week's feed cycle, mapped to the actual evidence — usually less impressive than the headline, occasionally more.
What was added, revised, or downgraded in the Wellness Radar Manual this week — and the new evidence behind the change.
Faster-moving items — new FDA action, pipeline news, regulatory updates, supplement market shifts. One sentence each, linked.
The FDA approved semaglutide for chronic kidney disease in T2D last week, on the strength of the FLOW trial — 24% reduction in the primary renal composite, trial stopped early for efficacy.
Three things this changes: (1) Nephrology referrals. Pre-FLOW, a CKD patient with T2D was on an SGLT-2 first. Now there's a second hard-endpoint option on the same prescription pad. (2) Insurance coverage. Cardio-renal endpoints make payor approval much cleaner than a weight indication ever did. (3) The pipeline. Tirzepatide's renal trial reads out in 2027 — and a positive readout there reshapes the class again…
[Sample preview · subscribe to read the full issue]